Biotech News
Related news
REPLReplimune Group2026-08-10 12:00 EST
Replimune Announces Pricing of $150 Million Underwritten Offering
ZNTLZentalis2026-08-17 20:01 EST
Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
ZNTLZentalis2026-08-14 02:23 EST
Zentalis Pharmaceuticals Announces Pricing of Underwritten Public Offering
ERASErasca2026-07-13 20:19 EST
Erasca Announces Proposed Public Offering of $500 Million of Common Stock
ERASErasca2026-07-15 20:01 EST
Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
KURAKura Oncology2026-09-09 11:00 EST
Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes
IMTXImmatics2026-07-17 14:25 EST
Immatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026
TEVATeva Pharmaceutical Industries2026-09-07 07:53 EST
Teva Announces Launch of Offering of Senior Notes
IMTXImmatics2026-08-18 11:00 EST
Immatics Announces Second Quarter 2026 Financial Results and Business Update
REGNRegeneron Pharmaceuticals2026-07-31 11:00 EST
Regeneron Awards $150,000 to Winners of the 2026 Regeneron Prize for Creative Innovation
Immatics
TCR-Based Solid Tumor Immunotherapy Immatics develops engineered T-cell therapies and TCR bispecifics directed against intracellular cancer targets presented by HLA molecules. PRAME Franchise The company has built multiple modalities around PRAME, a target expressed across more than 50 cancers. Anzu-cel Anzu-cel is an autologous...
Recent company news
IMTXImmatics2026-08-25 11:00 EST
Immatics Announces $150 Million Underwritten Offering
IMTXImmatics2026-08-18 11:00 EST
Immatics Announces Second Quarter 2026 Financial Results and Business Update
IMTXImmatics2026-07-17 14:25 EST
Immatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026
IMTXImmatics2026-06-01 12:00 EST
Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting
IMTXImmatics2026-05-31 13:00 EST
Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer
Stock data
- Close
- 8.82 USD
- Market cap
- 1.37B USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States